[A19-95] Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.03.2020
Project no.:
A19-95
Commission:
Commission awarded on 21.11.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Treatment-naive adults with advanced renal cell carcinoma
In favourable and intermediate risk profile: added benefit not proven; in poor risk profile: indication of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-41 | Avelumab (renal cell carcinoma) - Addendum to Commission A19-95 | Commission completed |
| A20-34 | Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G17-09 | Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V | Commission completed |
| G20-06 | Avelumab (renal cell carcinoma) - Addendum to Commission A19-95 | Commission completed |
| A21-23 | Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |